Bio-Path Holdings Inc.
| NASDAQ: BPTH | Healthcare / Biotechnology / USA |
| 0.3550 | -0.0150 | -4.05% | Vol 60.36K | 1Y Perf -88.99% |
| Oct 4th, 2023 15:59 DELAYED |
| BID | 0.3400 | ASK | 0.3900 | ||
| Open | 0.3700 | Previous Close | 0.3700 | ||
| Pre-Market | - | After-Market | - | ||
| - - | - -% |
| Target Price | 11.00 | Analyst Rating | Strong Buy 1.00 | |
| Potential % | 3.00K | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | — - | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | — - | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Price Range Ratio 52W % | 0.15 | Earnings Rating | Strong Buy | |
| Market Cap | 4.07M | Earnings Date | 21st Nov 2023 | |
| Alpha | 0.04 | Standard Deviation | 0.92 | |
| Beta | 1.37 |
Today's Price Range 0.34000.3700 | 52W Range 0.35013.54 | 5 Year PE Ratio Range -2.60-2.60 |
Summary:
Sell
| Technical Indicators: | Neutral |
| Moving Averages: | Strong Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | 2.49% | ||
| 1 Month | -7.38% | ||
| 3 Months | -79.21% | ||
| 6 Months | -73.57% | ||
| 1 Year | -88.99% | ||
| 3 Years | -91.06% | ||
| 5 Years | -97.11% | ||
| 10 Years | -99.94% |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -48.04 | |||
ROE last 12 Months | -68.29 | |||
ROA (5Y Avg) | -20.93 | |||
ROA last 12 Months | -62.96 | |||
ROC (5Y Avg) | -86.85 | |||
ROC last 12 Months | -60.94 | |||
Return on invested Capital Q | -19.57 | |||
Return on invested Capital Y | -14.89 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | - |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -0.90 | ||||
| 0.83 | ||||
| - | ||||
| - | ||||
| -1.30 | ||||
| -1.80 | ||||
| 0.83 | ||||
| 2.03 | ||||
| 48.68K | ||||
| Forward PE | -0.28 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 6.20 | ||||
| 8.20 | ||||
| 0.01 | ||||
| 0.02 | ||||
| - | ||||
| Leverage Ratio | 1.10 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.00 | ||||
| 0.00 | ||||
| - | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q02 2023 | -0.52 | -0.53 | -1.92 |
| Q01 2023 | -0.45 | -0.66 | -46.67 |
| Q04 2022 | -0.45 | -0.53 | -17.78 |
| Q03 2022 | -0.46 | -0.49 | -6.52 |
| Q02 2022 | -0.50 | -0.42 | 16.00 |
| Q01 2022 | -0.46 | -0.47 | -2.17 |
| Q04 2021 | -0.32 | -0.59 | -84.38 |
| Q03 2021 | -0.33 | -0.29 | 12.12 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 9/2023 QR | -0.34 | 19.05 | Positive |
| 12/2023 QR | -0.28 | 34.88 | Positive |
| 12/2023 FY | -1.70 | 10.99 | Positive |
| 12/2024 FY | -1.28 | 32.98 | Positive |
| Next Report Date | 21st Nov 2023 |
| Estimated EPS Next Report | -0.34 |
| Estimates Count | 1 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 60.36K |
| Shares Outstanding | 11.46K |
| Shares Float | 11.05M |
| Trades Count | 169 |
| Dollar Volume | 21.51K |
| Avg. Volume | 152.43K |
| Avg. Weekly Volume | 68.83K |
| Avg. Monthly Volume | 56.34K |
| Avg. Quarterly Volume | 332.13K |
Bio-Path Holdings Inc. (NASDAQ: BPTH) stock closed at 0.37 per share at the end of the most recent trading day (a -2.37% change compared to the prior day closing price) with a volume of 24.74K shares and market capitalization of 4.07M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 9 people. Bio-Path Holdings Inc. CEO is Peter H. Nielsen.
The one-year performance of Bio-Path Holdings Inc. stock is -88.99%, while year-to-date (YTD) performance is -75.5%. BPTH stock has a five-year performance of -97.11%. Its 52-week range is between 0.3501 and 3.542, which gives BPTH stock a 52-week price range ratio of 0.15%
Bio-Path Holdings Inc. currently has a PE ratio of -0.90, a price-to-book (PB) ratio of 0.83, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -62.96%, a ROC of -60.94% and a ROE of -68.29%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from Bio-Path Holdings Inc., there were 0 positive earnings surprise and 4 negative earnings surprise. The company has EPS estimate of $-0.34 for the next earnings report. Bio-Path Holdings Inc.’s next earnings report date is 21st Nov 2023.
The consensus rating of Wall Street analysts for Bio-Path Holdings Inc. is Strong Buy (1), with a target price of $11, which is +2 998.59% compared to the current price. The earnings rating for Bio-Path Holdings Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Bio-Path Holdings Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Bio-Path Holdings Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 38.92, ATR14 : 0.04, CCI20 : -89.56, Chaikin Money Flow : 0.04, MACD : -0.04, Money Flow Index : 33.86, ROC : -9.76, RSI : 38.49, STOCH (14,3) : 28.88, STOCH RSI : 0.72, UO : 33.25, Williams %R : -71.12), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Bio-Path Holdings Inc. in the last 12-months were:
Bio-Path Holdings Inc.
Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. The company's lead drug candidate, prexigebersen, is in the efficacy portion of Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. Its other drugs are BP1002 and BP1003.
CEO: Peter H. Nielsen
Telephone: +1 832 742-1357
Address: 4710 Bellaire Boulevard, Bellaire 77401, TX, US
Number of employees: 9
